¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Assay and drug development technologies."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • drug-induced hemolysis
    ¾à¹°À¯¹ß¿ëÇ÷
  • drug-induced hemolytic anemia
    ¾à¹°À¯¹ß¿ëÇ÷ºóÇ÷
  • drug-induced hepatitis
    ¾à¹°À¯¹ß°£¿°
  • drug-induced immune complex
    ¾à¹°À¯¹ß¸é¿ªº¹ÇÕü
  • drug-induced jaundice
    ¾à¹°À¯¹ßȲ´Þ
  • drug-induced purpura
    ¾à¹°À¯¹ßÀÚ»ö¹Ý
  • drug-induced retinopathy
    ¾à¹°À¯¹ß¸Á¸·º´(Áõ)
  • drug-induced rhinitis
    ¾à¹°À¯¹ßÄÚ¿°, ¾à¹°À¯¹ßºñ¿°
  • drug-resistant
    ¾à¹°ÀúÇ×-
  • designer drug
    º¯Á¶¾à¹°
  • fixed drug eruption
    °íÁ¤¾à¹°¹ßÁø, °íÁ¤¾àÁø
  • gateway drug
    Åë·Î¼ö´Ü¾à¹°, ½À°üÇü¼º¾à¹°
  • generic drug name
    ÀϹݾà¸í
  • hallucinogenic drug
    ȯ°¢Á¦
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • drug-fast
    ¾àÁ¦³»¼º-
  • drug-induced
    ¾à¹°À¯¹ß-, ¾àÁ¦À¯¹ß-
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø½Å°æ±ÙÂ÷´ÜÁ¦
  • designer drug
    º¯Á¶¾à¹°
  • drug dependence
    ¾à¹°ÀÇÁ¸
  • drug detection
    ¾à¹°°ËÃâ
  • drug eruption
    ¾à¹°¹ßÁø
  • drug evaluation
    ¾à¹°Æò°¡
  • drug exanthem
    ¾à¹°¹ßÁø
  • drug idiosyncrasy
    ¾à¹°Æ¯ÀÌüÁú
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • drug interference
    ¾à¹°°£¼·
  • drug plant
    ¾àÃÊ
  • drug potentiation
    ¾à¹°°­È­ÀÛ¿ë, ¾à¹°»ó½ÂÀÛ¿ë
  • drug psychosis
    ¾à¹°Á¤½Åº´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • hydrophilic drug
    Ä£¼ö¼º ¾àÁ¦.
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • photoallergic drug eruption
    ±¤¾Ë·¹¸£±â¼º ¾àÁø
  • prescription drug
    󹿾à.
  • pressor drug
    Ç÷¾Ð»ó½ÂÁ¦.
  • prolonged action drug
    Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • prolonged action drug
    Ưȿ¼º ¾àÁ¦(÷åüùàõå·ð¥), Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
  • psychedelic drug
    ȯ°¢Á¦
  • psychoactive drug
    Á¤½ÅȰ¼º ¾à¹°(?)
  • psychoactive drug
    Á¤½ÅȰ¼ºÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • chills and fever
    °£Çæ¹ß¿­.
  • coeloms and septa
    ü°­°ú Áß°Ý
  • cones and rods
    Ãßü°£Ã¼, ½Ã¼¼Æ÷
  • confluent and reticulated papillomatosis
    À¶ÇÕ¼º ¸Á»ó(ë×ùêàõ ØÑßÒ) À¯µÎÁ¾Áõ(êáÔéðþñø)
  • cup and ball osteotomy
    ¹èÇü Àý°ñ¼ú(ÛÍû¡ï¹Íéâú), ÄÅ Àý°ñ¼ú, ¿äö»ó°ñ Àý°ñ¼ú(èêôÈßÒÍéôîÍéâú).
  • cutting and bending plier
    Àý´Ü°âÀÚ(ôîÓ¨ÌÆí­).
  • diastolic dip and plateau
    È®Àå±âÁ¦°ö±Ù ¸ð¾ç.
  • diffuse and macular atrophic dermatosis
    ±¤¹üÀ§ ¹Ý¼º À§Ãà ÇǺκ´
  • dilatation and curettage =D & C
    °æ°üÈ®Àå ÀÚ±Ã¼ÒÆÄ(¼ú)(Ìòηüªíåí­ÏàḠâú).
  • discoloration and staining of teeth
    Ä¡¾ÆÀÇ Âø»ö(öÍ䳡­ó·ßä).
  • ear nose and throat =ENT
    À̺ñÀÎÈİú
  • encephalomyelitis,postinfectious and postvaccinal
    -°¨¿°(Á¢Á¾)ÈÄ ³úô¼ö¿°
  • esophagus,atresia and fidtula
    Æó¼â ´©°ü
  • esophagus,rings and webs
    ¹°°¥Äû(¸·¾ç±¸Á¶)
  • et al ; and others
    µé, µî. tat<ºÒ>[ÀÇ]»óÅÂ(ßÒ÷¾),
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
DBI development at birth index; phenformin hydrochloride
dev development; deviation
devel development
EDDS electronic development delivery system
GRANDDAD growth delay-aged facies-normal development-deficiency of subcutaneous fat [syndrome]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
DIC Drug Information Center
DRP Drug Related Problems
D.U.E. Drug Use Evaluation
DUR Drug Use Review
DUR Drug Utilization Review
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antispirochetal drug
    Ç×½ºÇÇ·ÎÇìŸ ¾à
  • antithyroid drug
    Ç×°©»ó¼± ¾à
  • bioreductive drug
    »ýü ȯ¿ø¼º ¾àÁ¦
  • bullous drug-induced exanthema
    ¾à¹°¿¡ ÀÇÇÑ ¼öÆ÷¼º ¹ßÁø
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • cholinergic drug
    Äݸ° ÀÛ¿ë ¾à
  • common drug
    º¸Åë ¾à
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±Ù ºÀ¼â ¾à¹°
  • designer drug
    º¯Á¶ ¾à¹°, ³²¿ë ¾à¹°
  • doping : the action of administering a drug to someone before a sports event
    originally to a horse before a race
    ; the substance thus administered.
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
    µ¿ÀǾî=medicine. 1. º´À̳ª »óó¸¦ Ä¡·áÇϱâ À§ÇØ ¸Ô°Å³ª ¹Ù¸£°Å³ª ÁÖ»çÇÏ´Â ¹°Áú
  • drug abstinence
    ¾à¹° ±Ý´Ü, ±Ý´Ü
  • drug acne
    ¾à¹°¼º ¿©µå¸§
  • drug addiction
    ¸¶¾à »ó½À, ¾à¹° ½À°ü¼º Áßµ¶
  • drug adsorption
    ¾à¹° ÈíÂø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
drug administration routes The various ways of administering a drug or other chemical to a site in a patient or animal from where the chemical is absorbed into the blood and delivered to the target tissue.
(12 Dec 1998)
drug administration schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
(12 Dec 1998)
drug allergy Sensitivity (hypersensitivity) to a drug or other chemical.
(05 Mar 2000)
drug, antihypertensive As the name clearly implies, a drug aimed at reducing high blood pressure (hypertension).
(12 Dec 1998)
drug, anti-infective A medication capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright.
(12 Dec 1998)
drug approval Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
(12 Dec 1998)
drug carriers Substances that facilitate time-controlled delivery, organ-specific targeting, protection, prolonged in vivo function, and decrease of toxicity of drugs. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
(12 Dec 1998)
drug combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. It is differentiated from drug therapy, combination in which two or more drugs are administered separately for a combined effect.
(12 Dec 1998)
drug compounding The preparation, mixing, and assembling of a drug.
(12 Dec 1998)
drug costs The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (fees, pharmaceutical or prescription fees).
(12 Dec 1998)
drug delivery The method and route used to provide medication.
(16 Dec 1997)
drug delivery systems Systems of administering drugs through controlled delivery so that an optimum amount reaches the target site. Drug delivery systems encompass the carrier, route, and target.
(12 Dec 1998)
drug dependence Use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed. Drug dependence is a compulsion to take a drug to produce a desired effect or prevent unpleasant effects when the drug is withheld. Risk factors for drug abuse include: low self esteem, inability to deal with stress and emotional instability. Juveniles use drugs due to peer pressure. Signs of drug use in children include: a change in friends or group, long absences from home, poor performance in school, seclusion, stealing, lying, criminal behaviour, deteriorating family relationships, signs of drug intoxication and changes in behaviour. Commonly abused drugs include narcotic analgesic agents, benzodiazepines, cocaine, amphetamines, barbiturates, marijuana, LSD and phencyclidine. Many labs now offer quick and inexpensive urine drug screening. Psychological counseling and parental support will be necessary in children with this problem.
(27 Sep 1997)
drug design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
(12 Dec 1998)
drug eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • nuts and bolts
    (±â°èÀÇ)ÀÛµ¿ºÎ(ºÐ);¿îÀü;°æ¿µ;(»ç¹°ÀÇ)±âº» ¿äÁ¡
  • park-and-ride
    Â÷·Î ¿ª±îÁö °¡¼­ ÁÖÂ÷Çϰí ÀüÂ÷³ª ¹ö½º·Î °¥¾ÆÅ¸´Â (¹æ½Ä)
  • quick and dirty
    (Ä«¿îÅͽÄÀÇ)°£ÀÌ ½Ä´ç(snack bar)
  • rag-and-none man
    ³Õ¸¶ÁÖÀÌ
  • rank-and-file
    Æò»ç¿øÀÇ;(ÁöµµÀÚ°¡ ¾Æ´Ñ)ÀÏ¹Ý Á¶ÇÕ¿øÀÇ;¼­¹Î.ÀÏ¹Ý ´ëÁßÀÇ;(Àå±³°¡ ¾Æ´Ñ)»çº´ÀÇ
  • rank-and-filer
    »çº´;ÀϹݽùÎ;¼­¹Î;Æò»ç¿øµé;Æò´ç¿øµé
  • reach and frequency
    µµ´Þµµ¿Í µµ´Þ Ƚ¼ö(ÀÏ·ÃÀÇ ±¤°í Ȱµ¿À¸·Î ±× °­°í°¡ ¾î´À Á¤µµ ħÅõ Çߴ°¡¸¦ ÃøÁ¤ÇÒ ¶§ »ç¿ëµÇ´Â µÎ°¡Áö ¿ä¼Ò)
  • reaper and binder
    ¹ÙÀδõ(º£¾î¼­ ´Ù¹ßÀ» ¹­´Â ±â°è)
  • rest and recuperation
    (º´»çÀÇ)ÈÞ°¡¿Í ÈÞ¾ç
  • rhythm and blues
    ¸®µë ¾Øµå ºí·ç½º(ÈæÀÎ À½¾ÇÀÇ ÀÏÁ¾,rock'n'rollÀÇ ¸ðü)
  • right of visit (and search)
    =RIGHT OF SEARCH
  • right-and-left
    Á¿ìÀÇ;ÁÂ¿ì µÎ¼Õ(¹ß)ÀÇ
  • rock and roll
    =ROCK'N'ROLL
  • rock and rye
    ¶óÀÌ º¸¸® À§½ºÅ°¿¡ ¾óÀ½ »çÅÁÀ» ³Ö°í ¿À·»Áö.·¹¸óÀ» °¡¹ÌÇÑ À½·á
  • rough-and-ready
    Á¹¼Ó ÁÖÀÇÀÇ;Àӽú¯ÅëÀÇ;Àúµ¹ÀûÀÎ;µÚ¹ü¹÷À̵È;È¥Àü;³­Åõ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á